Comorbidities and systemic effects of chronic obstructive pulmonary disease

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 101-130

  Choudhury, Gourab ^a   Rabinovich, Roberto ^a   MacNee, William ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Comorbidities; Inflammation; Management strategy; Systemic effects

Indexed keywords

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COMORBIDITIES; INFLAMMATION; MANAGEMENT STRATEGY; SYSTEMIC EFFECTS;

ANEMIA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; LUNG NEOPLASMS; MUSCULAR ATROPHY; OSTEOPOROSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84893472850     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.10.007     Document Type: Review

References (259)

1. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
2. Chapman K.R., Mannino D.M., Soriano J.B., et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:188-207. 10.1183/09031936.06.00024505.
3. Celli B.R., MacNee W., Agusti A., et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
4. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2012, 45:291-300.
5. Agusti A.G. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2(4):367-370. [discussion: 371-2].
6. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185. 10.1183/09031936.00128008.
7. Ghoorah K., De Soyza A., Kunadian V. Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. Cardiol Rev 2013, 21:196-202.
8. Agarwal S.K., Heiss G., Barr R.G., et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 2012, 14(4):414-422. 10.1093/eurjhf/hfs016.
9. Mapel D.W., Dedrick D., Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005, 2(1):35-41.
10. Anthonisen N.R., Connett J.E., Enright P.L., Lung Health Study Research Group, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166(3):333-339.
11. Divo M., Cote C., de Torres J.P., et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186(2):155-161. 10.1164/rccm.201201-0034OC.
12. Holguin F., Folch E., Redd S.C., et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005, 128:2005-2011.
13. Bang K.M., Gergen P.J., Kramer R., et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993, 103(2):536-540.
14. Campo G., Guastaroba P., Marzocchi A., et al. Impact of chronic obstructive pulmonary disease on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013, 10.1378/chest.12-2313.
15. Hole D.J., Watt G.C., Davey-Smith G., et al. Impaired lung function and mortality risk in men and women: finding from the Renfrew and Paisley prospective population study. BMJ 1996, 313:711-715. [discussion: 715-6].
16. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107(11):1514-1519.
17. Iwamoto H., Yokoyama A., Kitahara Y., et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009, 179(1):35-40.
18. van Gestel Y.R., Flu W.J., van Kuijk J.P., et al. Association of COPD with carotid wall intima-media thickness in vascular surgery patients. Respir Med 2010, 104(5):712-716.
19. Ross R. The pathogenesis of atherosclerosis: aperspective for the 1990s. Nature 1993, 362(6423):801-809.
20. Agustí A., Edwards L.D., Rennard S.I., Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) Investigators, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7(5):e37483.
21. Celli B.R., Locantore N., Yates J., ECLIPSE Investigators, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185(10):1065-1072.
22. McAllister D.A., Maclay J.D., Mills N.L., et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012, 39:1097-1103. 10.1183/09031936.00124811.
23. Hurst J.R., Donaldson G.C., Perera W.R., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174(8):867-874.
24. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2013, 143(3):798-807. 10.1378/chest.12-0938.
25. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111(25):3481-3488.
26. Coulson J.M., Rudd J.H., Duckers J.M., et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: an 18 F-FDG PET pilot study. JNucl Med 2010, 51(9):1357-1360.
27. Lattimore J., Wilcox I., Nakhla S., et al. Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis 2005, 179(2):255-259.
28. Ichikawa H., Flores S., Kvietys P.R., et al. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ Res 1997, 81(6):922-931.
29. Hartmann G., Tschöp M., Fischer R., et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 2000, 12(3):246-252.
30. Savransky V., Nanayakkara A., Li J., et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007, 175(12):1290-1297.
31. Chen L., Einbinder E., Zhang Q., et al. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 2005, 172(7):915-920.
32. Thomson A.J., Drummond G.B., Waring W.S., et al. Effects of short-term isocapnic hyperoxia and hypoxia on cardiovascular function. JAppl Physiol 2006, 101:809-816.
33. Skwarski K.M., Morrison D., Barratt A., et al. Effects of hypoxia on renal hormonal balance in normal subjects and in patients with COPD. Respir Med 1998, 92(12):1331-1336.
34. Heindl S., Lehnert M., Criée C.P., et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001, 164:597-601.
35. Curtis B.M., O'Keefe J.H. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002, 77:45-54.
36. Cordero A., Bertomeu-Martínez V., Mazón P., et al. Clinical features and hospital complications of patients with acute coronary syndromes according to smoking habits. Med Clin (Barc) 2012, 138(10):422-428. 10.1016/j.medcli.2011.01.016.
37. Bernhard D., Wang X.L. Smoking, oxidative stress and cardiovascular diseases-do anti-oxidative therapies fail?. Curr Med Chem 2007, 14:1703-1712.
38. Brook R.D., Rajagopalan S. Particulate matter, air pollution, and blood pressure. JAm Soc Hypertens 2009, 3:332-350.
39. Talukder M.A., Johnson W.M., Varadharaj S., et al. Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. Am J Physiol Heart Circ Physiol 2011, 300(1):H388-H396.
40. Alessandri C., Basili S., Violi F., et al. Chronic Obstructive Bronchitis and Haemostasis Group. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994, 72(3):343-346.
41. Ashitani J.I., Mukae H., Arimura Y., et al. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002, 41(3):181-185.
42. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
43. Cote C., Zilberberg M.D., Mody S.H., et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007, 29:923-929.
44. Weber F.P. The prognostic significance of secondary polycythaemia in cardio-pulmonary cases. Proc R Soc Med 1913, 6:83-98.
45. Minet C., Vivodtzev I., Tamisier R., et al. Reduced six-minute walking distance, high fat-free-mass index and hypercapnia are associated with endothelial dysfunction in COPD. Respir Physiol Neurobiol 2012, 183(2):128-134. 10.1016/j.resp.2012.06.017.
46. Barr R.G., Mesia-Vela S., Austin J.H., et al. Impaired flow mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 2007, 176:1200-1207.
47. Eickhoff P., Valipour A., Kiss D., et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178:1211-1218.
48. Maclay J.D., McAllister D.A., Mills N.L., et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:513-520.
49. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. JAm Coll Cardiol 2010, 55:1318-1327.
50. Sabit R., Bolton C.E., Edwards P.H., et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(12):1259-1265.
51. Mills N.L., Miller J.J., Anand A., et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008, 63(4):306-311.
52. McAllister D.A., Maclay J.D., Mills N.L., et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:1208-1214.
53. Maclay J.D., McAllister D.A., Rabinovich R., et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012, 67:606-612.
54. Rutten F.H., Cramer M.J., Grobbee D.E., et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005, 26(18):1887-1894.
55. Boudestein L.C., Rutten F.H., Cramer M.J., et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009, 11(12):1182-1188. 10.1093/eurjhf/hfp148.
56. Mascarenhas J., Lourenco P., Lopes R., et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008, 155:521-525.
57. De Blois J., Simard S., Atar D., et al. COPD predicts mortality in heart failure: the Norwegian Heart Failure Registry. JCard Fail 2010, 16:225-229.
58. Iversen K.K., Kjaergaard J., Akkan D., et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010, 12(7):685-691. 10.1093/eurjhf/hfq050.
59. Watz H., Waschki B., Meyer T., et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD, role of hyperinflation. Chest 2010, 138(1):32-38.
60. Barr R.G., Bluemke D.A., Ahmed F.S., et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. NEngl J Med 2010, 362(3):217-227.
61. Shih H., Webb C., Conway W., et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988, 94:44-48.
62. Sekine Y., Kesler K.A., Behnia M., et al. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest 2001, 120:1783-1790.
63. Mathew J.P., Fontes M.L., Tudor I.C., et al. Amulticenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004, 291:1720-1729.
64. Ryynänen O.P., Soini E.J., Lindqvist A., et al. Bayesian predictors of very poor health related quality of life and mortality in patients with COPD. BMC Med Inform Decis Mak 2013, 13:34. 10.1186/1472-6947-13-34.
65. Reed R.M., Eberlein M., Girgis R.E., et al. Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am J Med 2012, 125(12):1228.e13-1228.e22. 10.1016/j.amjmed.2012.05.018.
66. Hawkins N.M., Huang Z., Pieper K.S., et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009, 11(3):292-298. 10.1093/eurjhf/hfp001.
67. Donaldson G.C., Hurst J.R., Smith C.J., et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137(5):1091-1097.
68. Mackay D.F., Irfan M.O., Haw S., et al. Meta-analysis of the effect of comprehensive smoke-free legislation on acute coronary events. Heart 2010, 96:1525-1530.
69. Sin D.D., Man S.F., Marciniuk D.D., et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177(11):1207-1214. 10.1164/rccm.200709-1356OC.
70. Calverley P.M., Anderson J.A., Celli B., et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010, 65(8):719-725. 10.1136/thx.2010.136077.
71. Verhamme K.M., Afonso A., Romio S., et al. Use of tiotropium Respimat(R) SMI vs. tiotropium Handihaler(R) and mortality in patients with COPD. Eur Respir J 2013, 42:606-615.
72. Celli B., Decramer M., Leimer I., et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010, 137(1):20-30. 10.1378/chest.09-0011.
73. Dransfield M.T., Rowe S.M., Johnson J.E., et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008, 63(4):301-305.
74. Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009, 9:32. 10.1186/1471-2466-9-32.
75. Mancini G.B., Etminan M., Zhang B., et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. JAm Coll Cardiol 2006, 47:2554-2560.
76. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. NEngl J Med 1998, 339(8):489-497.
77. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
78. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
79. Heart Failure Society of America, Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure practice guideline. JCard Fail 2010, 16:e1-e194.
80. Andreas S., Anker S.D., Scanlon P.D., et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005, 128(5):3618-3624.
81. Rutten F.H., Zuithoff N.P., Hak E., et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170(10):880-887. 10.1001/archinternmed.2010.112.
82. Hawkins N.M., Jhund P.S., Simpson C.R., et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010, 12(1):17-24. 10.1093/eurjhf/hfp160.
83. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, (4). CD003566.
84. Stefan M.S., Rothberg M.B., Priya A., et al. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012, 67(11):977-984. 10.1136/thoraxjnl-2012-201945.
85. Ekström M.P., Hermansson A.B., Ström K.E. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187(7):715-720. 10.1164/rccm.201208-1565OC.
86. Mortensen E.M., Copeland L.A., Pugh M.J., et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009, 10:45. 10.1186/1465-9921-10-45.
87. Agusti A.G., Noguera A., Sauleda J., et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
88. Gosselink R., Troosters T., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996, 153:976-980.
89. Shrikrishna D., Hopkinson N.S. Chronic obstructive pulmonary disease: consequences beyond the lung. Clin Med 2012, 12:71-74.
90. Decramer M., Gosselink R., Troosters T., et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997, 10:417-423.
91. Swallow E.B., Reyes D., Hopkinson N.S., et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007, 62:115-120.
92. Seymour J.M., Spruit M.A., Hopkinson N.S., et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010, 36:81-88.
93. Shrikrishna D., Hopkinson N.S. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Med 2009, 5:7-13. COPD Update.
94. Hopkinson N.S., Polkey M.I. Does physical inactivity cause chronic obstructive pulmonary disease?. Clin Sci 2010, 118:565-572.
95. Shrikrishna D., Patel M., Tanner R.J., et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012, 10.1183/09031936.00170111.
96. Wust R.C., Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2007, 2:289-300.
97. Schols A.M., Soeters P.B., Dingemans A.M., et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993, 147:1151-1156.
98. Bernard S., LeBlanc P., Whittom F., et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:629-634.
99. Mostert R., Goris A., Weling-Scheepers C., et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000, 94:859-867.
100. Marquis K., Debigare R., Lacasse Y., et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:809-813.
101. Whittom F., Jobin J., Simard P.M., et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998, 30:1467-1474.
102. Gosker H.R., Engelen M.P., van Mameren H., et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002, 76:113-119.
103. Sala E., Roca J., Marrades R.M., et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:1726-1734.
104. Jobin J., Maltais F., Doyon J.F., et al. Chronic obstructive pulmonary disease: capillarity and fiber characteristics of skeletal muscle. JCardiopulm Rehabil 1998, 18:432-437.
105. Allaire J., Maltais F., Doyon J.F., et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax 2004, 59:673-678.
106. Rabinovich R.A., Bastos R., Ardite E., et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J 2007, 29:643-650.
107. Engelen M.P., Deutz N.E., Wouters E.F., et al. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1488-1492.
108. Plant P.J., Brooks D., Faughnan M., et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease (COPD). Am J Respir Cell Mol Biol 2010, 42:461-471.
109. Rabinovich R.A., Vilaro J. Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010, 16:123-133.
110. Dekhuijzen P.N., Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur Respir J 1992, 5:997-1003.
111. Decramer M., de Bock V., Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:1958-1964.
112. Hopkinson N.S., Man W.D., Dayer M.J., et al. Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur Respir J 2004, 24(1):137-142.
113. Takabatake N., Nakamura H., Abe S., et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1179-1184.
114. Preedy V.R., Smith D.M., Sugden P.H. The effects of 6 hours of hypoxia on protein synthesis in rat tissues invivo and invitro. Biochem J 1985, 228:179-185.
115. 2 levels cause mitochondrial dysfunction and impair cell proliferation. JBiol Chem 2011, 286:37067-37076.
116. Yende S., Waterer G.W., Tolley E.A., et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006, 61:10-16.
117. Remels A.H., Gosker H.R., Schrauwen P., et al. TNF-α impairs regulation of muscle oxidative phenotype: implications for cachexia?. FASEB J 2010, 24:5052-5062.
118. Pinto-Plata V.M., Müllerova H., Toso J.F., et al. C-Reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006, 61:23-28.
119. Ries A.L., Bauldoff G.S., Carlin B.W., et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131:4S-42S.
120. Meyer A., Zoll J., Charles A.L., et al. Skeletal muscle mitochondrial dysfunction during chronic obstructive pulmonary disease: central actor and therapeutic target. Exp Physiol 2013, 98:1063-1078.
121. MacIntyre N.R. Oxygen therapy and exercise response in lung disease. Respir Care 2000, 45:194-200.
122. Cardellach F., Alonso J.R., López S., et al. Effect of smoking cessation on mitochondrial respiratory chain function. JToxicol Clin Toxicol 2003, 41(3):223-228.
123. Koechlin C., Couillard A., Simar D., et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease?. Am J Respir Crit Care Med 2004, 169:1022-1027.
124. Broekhuizen R., Wouters E.F., Creutzberg E.C., et al. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax 2005, 60:376-382.
125. Ettinger M.P. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 2003, 163(18):2237-2246.
126. Lehouck A., Boonen S., Decramer M., et al. COPD, bone metabolism, and osteoporosis. Chest 2011, 139(3):648-657. 10.1378/chest.10-1427.
127. Kanis J.A. WHO Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994, 46:368-381.
128. Graat-Verboom L., Wouters E.F., Smeenk F.W., et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009, 341:209-218.
129. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEngl J Med 2007, 356:775-789.
130. Vrieze A., de Greef M.H., Wijkstra P.J., et al. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 2007, 18:1197-1202.
131. Jorgensen N.R., Schwarz P., Holme I., et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: across sectional study. Respir Med 2007, 101:177-185.
132. Romme E.A., Murchison J.T., Edwards L.D., et al. CT measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. JBone Miner Res 2013, 10.1002/jbmr.1873.
133. Kjensli A., Falch J.A., Ryg M., et al. High prevalence of vertebral deformities in COPD patients: relationship to disease severity. Eur Respir J 2009, 33:1018-1024.
134. Mazokopakis E.E., Starakis I.K. Recommendations for diagnosis and management of osteoporosis in COPD men. ISRN Rheumatol 2011, 2011:901416.
135. Weinstein R.S., Wan C., Liu Q., et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010, 9:147-161.
136. Langhammer A., Forsmo S., Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone?. Int J Chron Obstruct Pulmon Dis 2009, 4:365-380.
137. Manolagas S.C., Weinstein R.S. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. JBone Miner Res 1999, 14(7):1061-1066.
138. Mathioudakis A.G., Amanetopoulou S.G., Gialmanidis I.P., et al. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial?. Respirology 2013, 18(1):147-153. 10.1111/j.1440-1843.2012.02265.
139. Liang B., Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine 2012, 42(1):190-195. 10.1007/s12020-011-9583-x.
140. Hardy R., Cooper M.S. Bone loss in inflammatory disorders. JEndocrinol 2009, 201(3):309-320.
141. Ritchlin C.T., Haas-Smith S.A., Li P., et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. JClin Invest 2003, 111(6):821-831.
142. Kovacic J.C., Lee P., Baber U., et al. Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. Atherosclerosis 2012, 221(1):176-182. 10.1016/j.atherosclerosis.2011.11.020.
143. Ebeling P.R. Osteoporosis in men. NEngl J Med 2008, 358(14):1474-1482.
144. Gennari L., Bilezikian J.P. Osteoporosis in men. Endocrinol Metab Clin North Am 2007, 36(2):399-419.
145. Plotkin L.I., Aguirre J.I., Kousteni S., et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. JBiol Chem 2005, 280(8):7317-7325.
146. Ringe J.D., Faber H., Farahmand P., et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006, 26(5):427-431.
147. Misiorowski W. Parathyroid hormone and its analogues-molecular mechanisms of action and efficacy in osteoporosis therapy. Endokrynol Pol 2011, 62(1):73-78.
148. Patel A.R., Hurst J.R. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011, 5(5):647-662. [review]. 10.1586/ers.11.62.
149. Kanis J.A., McCloskey E.V., Johansson H., National Osteoporosis Guideline Group, et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19(10):1395-1408.
150. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005, 82(1):53-59.
151. Collins P.F., Elia M., Stratton R.J. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology 2013, 10.1111/resp.12070.
152. Ferreira I.M., Brooks D., White J., et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, (12). CD000998. 10.1002/14651858.CD000998.pub3.
153. Schols A.M., Gosker H.R. The pathophysiology ofcachexia in chronic obstructive pulmonary disease. Curr Opin Support Palliat Care 2009, 3(4):282-287. 10.1097/SPC.0b013e328331e91c.
154. Cano N.J., Roth H., Court-Ortuné I., et al. Nutritional depletion in patients on long-term oxygen therapy and/or home mechanical ventilation. Eur Respir J 2002, 20:30-37.
155. Vermeeren M.A., Creutzberg E.C., Schols A.M., COSMIC Study Group, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006, 100:1349-1355.
156. Landbo C., Prescott E., Lange P., et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:1856-1861.
157. Fuenzalida C.E., Petty T.L., Jones M.L. The immune response to short nutritional intervention in advanced COPD. Am Rev Respir Dis 1990, 142(1):49-56.
158. DeBellis H.F., Fetterman J.W. Enteral nutrition inthe chronic obstructive pulmonary disease (COPD) patient. JPharm Pract 2012, 25(6):583-585. 10.1177/0897190012460827.
159. Malone A. Enteral formula selection: a review of selected product categories. Pract Gastroenterol 2005, 28:56-58.
160. de Batlle J., Sauleda J., Balcells E., et al. Association between Ω3 and Ω6 fatty acid intakes and serum inflammatory markers in COPD. JNutr Biochem 2011, 23(7):817-821.
161. World Health Organization Overweight and obesity: a new nutrition emergency? Monitoring the rapidly emerging public health problem of overweight and obesity: the WHO global database on body mass index. SCN News 2004, 5-12.
162. Poulain M., Doucet M., Major G.C., et al. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 2006, 174:1293-1299.
163. Pitta F., Troosters T., Spruit M.A., et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:972-977.
164. Dallman M.F., la Fleur S.E., Pecoraro N.C., et al. Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004, 145:2633-2638.
165. Franssen F.M., O'Donnell D.E., Goossens G.H., et al. Obesity and the lung: 5. Obesity and COPD. Thorax 2008, 63:1110-1117. 10.1136/thx.2007.086827.
166. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
167. Yudkin J.S. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S25-S28.
168. Young T., Palta M., Dempsey J., et al. The occurrence of sleep disordered breathing among middle-aged adults. N. Engl. JMed 1993, 328:1230-1235.
169. Young T., Peppard P.E., Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002, 165:1217-1239.
170. McNicholas W.T. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 2009, 180:692-700.
171. Fletcher E.C. Chronic lung disease in the sleep apnea syndrome. Lung 1990, 168(Suppl):751-761.
172. Ioachimescu O.C., Teodorescu M. Integrating the overlap of obstructive lung disease and obstructive sleep apnoea: OLDOSA syndrome. Respirology 2013, 18(3):421-431. 10.1111/resp.12062.
173. Clini E., Sturani C., Rossi A., et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002, 20:529-538.
174. Butterworth C.E., Fielding J.F., Finch C.A., et al. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968, 405:5-37.
175. John M., Hoernig S., Doehner W., et al. Anemia and inflammation in COPD. Chest 2005, 127(3):825-829.
176. Chambellan A., Chailleux E., Similowski T., et al. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005, 128:1201-1208.
177. Rutten E.P., Franssen F.M., Spruit M.A., et al. Anemia is associated with bone mineral density in chronic obstructive pulmonary disease. COPD 2013, 10:286-292.
178. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002, 16:87-96.
179. Schönhofer B., Wenzel M., Geibel M., et al. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998, 26:1824-1828.
180. Barnes P.J. Neural control of human airways in health and disease. Am Rev Respir Dis 1986, 134:1289-1314.
181. van Gestel A.J., Steier J. Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD). JThorac Dis 2010, 2(4):215-222.
182. Buda A.J., Pinsky M.R., Ingles N.B., et al. Effect of intrathoracic pressure on left ventricular performance. NEngl J Med 1979, 301:453-459.
183. Undem B.J., Kollarik M. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:355-360.
184. Dempsey J.A., Sheel A.W., St Croix C.M. Respiratory influences on sympathetic vasomotor outflow in humans. Respir Physiol Neurobiol 2002, 130:3-20.
185. Tug T., Terzi S.M., Yoldas T.K. Relationship between the frequency of autonomic dysfunction and the severity of chronic obstructive pulmonary disease. Acta Neurol Scand 2005, 112(3):183-188.
186. Purdue M.P., Gold L., Jarvholm B., et al. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax 2007, 62(1):51-56.
187. Punturieri A., Szabo E., Croxton T.L. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. JNatl Cancer Inst 2009, 101(8):554-559.
188. Mannino D.M., Aguayo S.M., Petty T.L., et al. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003, 163:1475-1480.
189. Tockman M.S., Anthonisen N.R., Wright E.C., et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987, 106(4):512-518.
190. Skillrud D.M., Offord K.P., Miller R.D. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986, 105(4):503-507.
191. Anthonisen N.R., Skeans M.A., Wise R.A., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233-239.
192. Wilson D.O., Weissfeld J.L., Balkan A., et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008, 178:738-744.
193. Young R.P., Hopkins R.J., Christmas T., et al. COPD prevalence is increased in lung cancer independence of age, gender and smoking history. Eur Respir J 2009, 34:380-386.
194. Papi A., Casoni G., Caramori G., et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004, 59(8):679-681.
195. Jacobson B.A., Alter M.D., Kratzke M.G., et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both invitro and invivo. Cancer Res 2006, 66(8):4256-4262.
196. Krysan K., Lee J.M., Dohadwala M., et al. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. JThorac Oncol 2008, 3(2):107-110.
197. Brody J.S., Spira A. Chronic obstructive pulmonary disease, inflammation and lung cancer. Proc Am Thorac Soc 2006, 3:535-538.
198. Yao H.W., Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009, 9:375-383.
199. Lin W.W., Karin M. Acytokine-mediated link between innate immunity, inflammation, and cancer. JClin Invest 2007, 117:1175-1183.
200. Wright J.G., Christman J.W. The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2003, 2:211-219.
201. Teramoto S., Kume H. The role of nuclear factor-kappa B activation in airway inflammation following adenovirus infection and COPD. Chest 2001, 119:1294-1295.
202. O'Byrne K.J., Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001, 85:473-483.
203. Parimon T., Chien J.W., Bryson C.L., et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:712-719.
204. van Gestel Y.R., Hoeks S.E., Sin D.D., et al. COPD and cancer mortality: the influence of statins. Thorax 2009, 64:963-967.
205. Young R.P., Hopkins R.J. How the genetics of lung cancer may overlap with COPD. Respirology 2011, 16(7):1047-1055. 10.1111/j.1440-1843.2011.02019.x.
206. Schwartz A.G., Ruckdeschel J.C. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:16-22.
207. Malhotra D., Thimmulappa R., Navas-Acien A., et al. Decline in Nrf2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. Am J Respir Crit Care Med 2008, 178:592-604.
208. Cho H.Y., Reddy S.P., Kleeberger S.R. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006, 8:76-87.
209. Krieken J.H., Hiemstra P.S. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 2006, 125:184-192.
210. Hill K., Geist R., Goldstein R.S., et al. Anxiety and depression in end-stage COPD. Eur Respir J 2008, 31(3):667-677. 10.1183/09031936.00125707.
211. Engstrom C.P., Persson L.O., Larsson S., et al. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996, 51:825-830.
212. Dowson C., Laing R., Barraclough R., et al. The use of the Hospital Anxiety and Depression Scale (HADS) in patients with chronic obstructive pulmonary disease: a pilot study. NZ Med J 2001, 114:447-449.
213. van Manen J.G., Bindels P.J., Dekker F.W., et al. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002, 57:412-416.
214. van Ede L., Yzermans C.J., Brouwer H.J. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999, 54:688-692.
215. Kunik M.E., Roundy K., Veazey C., et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005, 127:1205-1211.
216. Hanania N.A., Müllerova H., Locantore N.W., et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am JRespir Crit Care Med 2011, 183(5):604-611. 10.1164/rccm.201003-0472OC.
217. Anisman H., Merali Z., Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008, 85(1):1-74.
218. Almagro P., Calbo E., Ochoa-de-Echaguen A., et al. Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448.
219. Ng T.P., Niti M., Tan W.C., et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007, 167:60-67.
220. Fan V.S., Ramsey S.D., Giardino N.D., et al. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007, 167:2345-2353.
221. de Voogd J.N., Wempe J.B., Koëter G.H., et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009, 135:619-625. Prepublished online November 24, 2008. 10.1378/chest.08-0078.
222. Mannino D.M., Thorn D., Swensen A., et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32(4):962-969.
223. Rabinovich R.A., MacNee W. Chronic obstructive pulmonary disease and its comorbidities. Br J Hosp Med (Lond) 2011, 72(3):137-145.
224. Rana J.S., Mittleman M.A., Sheikh J., et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004, 27:2478-2484.
225. Poulain M., Doucet M., Drapeau V., et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis 2008, 5(1):35-41.
226. Chakrabarti B., Angus R.M., Agarwal S., et al. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 2009, 64(10):857-862.
227. Baker E.H., Janaway C.H., Philips B.J., et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006, 61(4):284-289.
228. Marquis K., Maltais F., Duguay V., et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. JCardiopulm Rehabil 2005, 25:226-232.
229. Fabbri L.M., Luppi F., Beghe B., et al. Complex chroniccomorbidities of COPD. Eur RespirJ 2008, 31:204-212. 10.1183/09031936.00114307.
230. Clini E., Crisafulli E., Radaeli A., et al. COPD and the metabolic syndrome: an intriguing association. Intern Emerg Med 2013, 8(4):283-289.
231. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007, 4:522-525.
232. van Eeden S.F., Sin D.D. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
233. Garcia-Rio F., Miravitlles M., Soriano J.B., et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11:63.
234. Sin D.D., Anthonisen N.R., Soriano J.B., et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28(6):1245-1257.
235. Gan W.Q., Man S.F., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
236. Fabbri L.M., Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007, 370:797-799.
237. Gea J., Barreiro E., Orozco-Levi M. Systemic inflammation in COPD. Clin Pulm Med 2009, 16:233-242.
238. Luppi F., Franco F., Beghe B., et al. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008, 5:848-856.
239. Rennard S.I. Inflammation in COPD: a link to systemic comorbidities. Eur Respir Rev 2007, 16:91-97.
240. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., et al. Systemic effects of smoking. Chest 2007, 131:1557-1566.
241. Gan W.Q., Man S.F., Sin D.D. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005, 127:558-564.
242. Maclay J.D., McAllister D.A., Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007, 12:634-641.
243. Sevenoaks M.J., Stockley R.A. Chronic obstructive pulmonary disease, inflammation and co-morbidity-a common inflammatory phenotype?. Respir Res 2006, 7:70.
244. Donaldson G.C., Seemungal T.A., Patel I.S., et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128:1995-2004.
245. Eagan T.M., Ueland T., Wagner P.D., et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 2010, 35:540-548.
246. Walter R.E., Wilk J.B., Larson M.G., et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008, 133:19-25.
247. Pinto-Plata V., Toso J., Lee K., et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc 2006, 3:465-466.
248. Sin D.D., Leung R., Gan W.Q., et al. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007, 7:13.
249. Bozinovski S., Hutchinson A., Thompson M., et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:269-278.
250. Sparrow D., Glynn R.J., Cohen M., et al. The relationship of the peripheral leukocyte count and cigarette smoking to pulmonary function among adult men. Chest 1984, 86:383-386.
251. Burnett D., Chamba A., Hill S.L., et al. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987, 2:1043-1046.
252. Aldonyte R., Jansson L., Piitulainen E., et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003, 4:11.
253. Hodge S.J., Hodge G.L., Reynolds P.N., et al. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol 2003, 285:L492-L499.
254. Domagala-Kulawik J., Hoser G., Dabrowska M., et al. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med 2007, 101:1338-1343.
255. Fairclough L., Urbanowicz R.A., Corne J., et al. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond) 2008, 114:533-541.
256. Sin D.D., Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009, 6:543-545.
257. Agusti A., Calverley P., Celli B., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122-136.
258. Dickens J.A., Miller B., Edwards L., et al. For the Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. Respir Res 2011, 12:146.
259. Vanfleteren L.E., Spruit M.A., Groenen M., et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187(7):728-735. 10.1164/rccm.201209-1665OC.